Development research to solve inflammasome transmission abnormality of familial Mediterranean fever by genome drug discovery

Development research to solve inflammasome transmission abnormality of familial Mediterranean fever by genome drug discovery - Genome drug discovery of familial Mediterranean fever

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030922

Enrollment

200

Registered

2018-01-23

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Mediterranean fever

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Familial Mediterranean fever patients meet the diagnostic criteria (FMF) and FMF and difficult cases clinical differential(Adult-onset Still's disease, etc.) -Patients can consent obtained in documents from the person and Daidaku person. -Samples (genomic information, serum, clinical information) collected in a previous study "Comprehensive analysis of the genetic factors and biomarkers involved in the pathogenesis of familial Mediterranean fever"

Exclusion criteria

Exclusion criteria: -Patients who do not correspond to the selection criteria

Design outcomes

Primary

Measure	Time frame
To identify novel genes that improve the diagnosis of FMF	—

Secondary

Measure	Time frame
To determine new biomarkers that assist the disease activity of FMF	—

Countries

Japan

Contacts

Public ContactTomohiro Koga

Nagasaki University Hospital First department of internal medicine

tkoga@nagasaki-u.ac.jp095-819-7874

Outcome results